Founded Year
2011Stage
Convertible Note | AliveTotal Raised
$202.09MLast Raised
$160M | 1 mo agoAbout Lygos
Lygos creates microbial-based end-to-end manufacturing solutions at the juncture of biology and technology to provide market-changing product opportunities. Lygos' first products -- malonic acid and derivatives -- replace low-quality petrochemical products produced at a high economic and environmental cost in countries without strong environmental protection programs. The company was founded in 2011 and is based in Berkeley, California.
Lygos Headquarter Location
1249 Eighth Street
Berkeley, California, 94710,
United States
510-416-5185
Expert Collections containing Lygos
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Lygos is included in 4 Expert Collections, including Synthetic Biology.
Synthetic Biology
305 items
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Advanced Materials
1,246 items
Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.
Cannabis
3,834 items
These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.
Advanced Manufacturing
55 items
Lygos Patents
Lygos has filed 13 patents.
The 3 most popular patent topics include:
- Dicarboxylic acids
- Virus families
- Biotechnology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/14/2017 | 5/10/2022 | Dicarboxylic acids, Food additives, Chemical processes, Potassium compounds, Biotechnology | Grant |
Application Date | 11/14/2017 |
|---|---|
Grant Date | 5/10/2022 |
Title | |
Related Topics | Dicarboxylic acids, Food additives, Chemical processes, Potassium compounds, Biotechnology |
Status | Grant |
Latest Lygos News
Apr 27, 2022
News provided by Share this article If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Flexible Solutions International Inc. (NYSE: FSI ) Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Flexible Solutions International Inc. (NYSE: FSI ) in connection with the proposed merger of FSI with Lygos, Inc. ("Lygos"). Under the terms of the merger agreement, Lygos issued $160 million worth of convertible notes with a 5.5% fixed annual interest rate and a five-year maturity. The conversion price of the convertible note will be set 12 months to the date of the note, and the pricing terms will be set upon the trading price of the future equity but will be set within a market capitalization range of no less than $250 million or no greater than $350 million. If you own FSI shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/fsi Natus Medical Incorporated (NASDAQ: NTUS ) Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Natus Medical Incorporated (NASDAQ: NTUS ), in connection with the proposed acquisition of NTUS by an affiliate of ArchiMed. Under the terms of the merger agreement, NTUS shareholders will receive $33.50 in cash for each share of NTUS common stock owned. If you own NTUS shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/ntus American Campus Communities, Inc. (NYSE: ACC ) Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of American Campus Communities, Inc. (NYSE: ACC ), in connection with the proposed acquisition of ACC by Blackstone Inc. (NYSE: BX ). Under the terms of the merger agreement, ACC shareholders will receive $65.47 in cash for each share of ACC common stock owned. If you own ACC shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/acc Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI ) Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI ), in connection with the proposed acquisition of CMPI by Regeneron Pharmaceuticals, Inc. via a tender offer. Under the terms of the merger agreement, CMPI shareholders will receive $10.50 in cash for each share of CMPI common stock owned. If you own CMPI shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/cmpi SOURCE Weiss Law
Lygos Web Traffic
Lygos Rank
When was Lygos founded?
Lygos was founded in 2011.
Where is Lygos's headquarters?
Lygos's headquarters is located at 1249 Eighth Street, Berkeley.
What is Lygos's latest funding round?
Lygos's latest funding round is Convertible Note.
How much did Lygos raise?
Lygos raised a total of $202.09M.
Who are the investors of Lygos?
Investors of Lygos include Paycheck Protection Program, CJ CheilJedang, LG Technology Ventures, Y Combinator, First Round Capital and 10 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.